On BTTV's 'Daily Calls' show, Anshul Jain, Head of Research at Lakshmishree Investment & Securities, provided a comprehensive analysis of various pharmaceutical stocks. His insights are particularly valuable for investors tracking companies such as Sun Pharmaceutical Industries Ltd, Dr Reddy’s Laboratories Ltd, Biocon Ltd, and Natco Pharma Ltd.
Large-Cap Pharma Insights
Addressing a query regarding Sun Pharmaceutical Industries Ltd, Jain noted that the stock was hovering near its breakout level of Rs 1,832. He pointed out a general technical weakness among major pharmaceutical companies, observing that heavyweights like Dr Reddy’s Laboratories, Lupin, and Cipla were struggling to sustain their breakout levels.
In contrast to these traditional large-caps, Jain highlighted Wockhardt Ltd as a standout performer, demonstrating sustained breakouts and delivering strong returns.
Mid-Cap and Small-Cap Opportunities
For investors exploring options beyond the top-tier names, Jain indicated that mid-cap and small-cap pharma stocks are effectively holding their breakout levels. He specifically lauded Natco Pharma for its impressive upward trajectory, rallying significantly from the Rs 928-940 range to reach Rs 1,200.
Jain advised accumulating stocks such as Natco Pharma, Mankind Pharma, and Emcure Pharmaceuticals during price dips or periods of market consolidation to build positions in the mid-to-small-cap segment. He also observed that Emcure Pharmaceuticals is sustaining its breakout levels and appears to be moving towards the Rs 2,000 mark.
Biocon: A Major Standout
Among all the discussed stocks, Jain identified Biocon as a significant standout, deeming it an excellent choice for investors focused on large-cap pharma stocks. He noted a 274-275 week coupling pattern on its charts, suggesting that a definitive breakout would be confirmed once the stock surpasses the Rs 416 level.
"If you want to invest, Biocon looks great," Jain stated on BTTV.
Disclaimer: The views and advice expressed by market analysts are for informational purposes only. Readers are strongly encouraged to consult with a qualified financial advisor before making any investment decisions.